Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 6356 participants.

Also called NCT06186037

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 6,356 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06186037
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06186037. Randomized; no masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2029-02-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention
Acronym
ALMIGHTY
Condition
Dyslipidemias
Condition
Primary Prevention
Intervention (Drug)
Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg
Intervention (Drug)
Mono drug group of Rosuvastatin 20 mg
Lead sponsor
Saint Vincent's Hospital, Korea (class: other)

Record details

Record id
cardio:ct-nct06186037
Content hash
1ca824f26daedd4b7200357be1de61dad70b5927b7b3486fea701580ba075e90